Long-term Experience and Outcomes of Programmatic Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 Infection in Senegal, West Africa. (30th March 2020)

• Record Type: Journal Article
• Authors: Raugi, Dana N; Ba, Selly; Cisse, Ousseynou; Diallo, Khardiata; Tamba, Ibrahima Tito; Ndour, Cheikh; Badiane, Ndeye Mery Dia; Fortes, Louise; Diallo, Mouhamadou Baïla; Faye, Dominique; Smith, Robert A; Sall, Fatima; Toure, Macoumba; Sall, ElHadji Ibrahima; Diallo Agne, Habibatou; Faye, Khadim; Diatta, Jean Philippe; Sy, Marie Pierre; Chang, Ming; Diaw, Binetou; Sambou, Jacques; Bakhoum, Raphael; Sy, Mame Demba; Niang, Alassane; Malomar, Jean Jacques; Coombs, Robert W; Hawes, Stephen E; Ndoye, Ibra; Kiviat, Nancy B; Sow, Papa Salif; Seydi, Moussa; Gottlieb, Geoffrey S;
• Is Part Of: Clinical infectious diseases. Volume 72:Number 3(2021)
• Page Start: 369
• Page End: 378
• Publication Date: 2020-03-30
• Subjects: HIV-2 -- antiretroviral therapy -- viral suppression -- 90-90-90 -- HIV treatment; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciaa277
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Background: Programmatic treatment outcome data for people living with human immunodeficiency virus type 2 (HIV-2) in West Africa, where the virus is most prevalent, are scarce. Methods: Adults with HIV-2 initiating or receiving antiretroviral therapy (ART) through the Senegalese national AIDS program were invited to participate in this prospective, longitudinal observational cohort study. We analyzed HIV-2 viral loads, CD4 cell counts, antiretroviral drug resistance, loss to follow-up, and mortality. We also examined changes in treatment guidelines over time and assessed progress toward the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 targets for HIV-2. Results: We enrolled 291 participants at 2 sites for 926.0 person-years of follow-up over 13 years. Median follow-up time was 2.2 years per participant. There were 21 deaths reported (7.2%), and 117 individuals (40.2%) were lost to follow-up, including 43 (14.7%) who had an initial visit but never returned for follow-up. CD4 counts and HIV-2 viral suppression (< 50 copies/mL) at enrollment increased over calendar time. Over the study period, 76.7% of plasma viral loads for participants receiving ART were suppressed, and median CD4 gain was 84 cells/μL in participants' first 2 years on study. Since the UNAIDS 90-90-90 strategy was published, 88.1% of viral loads were suppressed. Fifteen percent of patients experienced virologic failure with no known resistance mutations, while 56% had evidence of multiclass drug resistance. Conclusions: Participants in the Senegalese national AIDS program are initiating ART earlier in the course of disease, and more modern therapeutic regimens have improved outcomes among those receiving therapy. Despite these achievements, HIV-2 treatment remains suboptimal, and significant challenges to improving care remain. Abstract : This study summarizes 13 years' experience following people with Human Immunodeficiency Virus Type 2 (HIV-2) receiving antiretroviral therapy (ART) in Senegal. Earlier ART initiation and more modern therapeutic regimens have improved outcomes. However, HIV-2 treatment remains suboptimal, and viral suppression rates remain below 90%.